Yu Du

Yu Du

Auto-generated profile, based on publicly available information

Yu Du

Global Statistical Science Eli Lilly and Company Indianapolis Indiana USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2018 in Journal of Biopharmaceutical Statistics
Verified
Journal Article
Closed access
YDYu Du
Yu Du
JYJun Yin
Jun Yin
DSDaniel J. Sargent
Daniel J. Sargent
SMSumithra J. Mandrekar
Sumithra J. Mandrekar
Phase I designs traditionally use the dose-limiting toxicity (DLT), a binary endpoint from the first treatment cycle, to identify the maximum-tolerated dose (MTD) assuming a monotonically increasing relationship between dose and efficacy. In this article, we establish a general framework for a multi-stage adaptive design where we jointly model a continuous efficacy outcome and continuous/quasi-continuous toxicity endpoints from multiple treatment cycles. The normalized Total Toxicity Profile (nTTP) is used as an illustration for quasi-continuous toxicity endpoints, and we replace DLT with nTTP to take into account multiple grades and types of toxicities. In addition, the proposed design accommodates non-monotone dose-efficacy relationships, and longitudinal toxicity data in effort to capture the adverse events from multiple cycles. Stage 1 of our design uses toxicity data to perform dose-escalation and identify a set of initially allowable (safe) doses; stage 2 of our design incorporates an efficacy outcome to update the set of allowable doses for each new cohort and randomizes the new cohort of patients to the allowable doses with emphasis towards those with higher predicted efficacy. Stage 3 uses all data from all treated patients at the end of the trial to make final recommendations. Simulations showed that the design had a high probability of making the correct dose selection and good overdose control across various dose-efficacy and dose-toxicity scenarios. In addition, the proposed design allows for early termination when all doses are too toxic. To our best knowledge, the proposed dual-endpoint dose-finding design is the first such study to incorporate multiple cycles of toxicities and a continuous efficacy outcome.

2 September 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JYJun Yin
Jun Yin
YDYu Du
Yu Du
RQRui Qin
Rui Qin
SSShihao Shen
Shihao Shen
SMSumithra Mandrekar
Sumithra Mandrekar
Traditional dose-finding designs are substantially inefficient for targeted agents and cancer immunotherapies by failing to incorporate efficacy signals, mild and moderate adverse events, and late, cumulative toxicities. However, the lack of user-friendly software is a barrier to the practical use of the novel phase I designs, despite their demonstrated superiority of traditional 3+3 designs. To overcome these barriers, we present an R package, phase1RMD, which provides a comprehensive implementation of novel designs with repeated toxicity measures and early efficacy. A novel phase I repeated measures design that used a continuous toxicity score from multiple treatment cycles was implemented. Furthermore, in studies where preliminary efficacy is evaluated, an adaptive, multi-stage design to identify the most efficacious dose with acceptable toxicity was demonstrated. Functions are provided to recommend the next dose based on the data collected in a phase I trial, as well as to assess trial characteristics given design parameters via simulations. The repeated measure designs accurately estimated both the magnitude and direction of toxicity trends in late treatment cycles, and allocated more patients at therapeutic doses. The R package for implementing these designs is available from the Comprehensive R Archive Network. To our best knowledge, this is the first software that implement novel phase I dose-finding designs that simultaneously accounts for the multiple-grade toxicity events over multiple treatment cycles and a continuous early efficacy outcome. With the software published on CRAN, we will pursue the implementation of these designs in phase I trials in real-life settings.

14 May 2024 in Statistics in Medicine
Verified
Journal Article
Closed access
YDYu Du
Yu Du
JLJianghao Li
Jianghao Li
SRSohini Raha
Sohini Raha
YQYongming Qu
Yongming Qu

15 July 2025 in Statistics in Medicine
Verified
Journal Article
Closed access
JSJiren Sun
Jiren Sun
TWTuo Wang
Tuo Wang
YYYanyao Yi
Yanyao Yi
TYTing Ye
Ting Ye
JSJun Shao
Jun Shao
YDYu Du
Yu Du